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Borut Peterlind
We investigated the effect of the functional insertion/
deletion (I/D) polymorphism in the angiotensin-converting
enzyme (ACE) gene on the response to interferon-β (IFN-β)
therapy in Croatian and Slovenian patients with multiple
sclerosis (MS). A total of 275 IFN-β treated MS patients [162
responders (Rs) and 113 nonresponders (NRs)] were
genotyped by PCR. The ACE I/D genotype distribution and
allele frequencies did not differ between female Rs and NRs.
However, male NRs tended to have a greater prevalence of
the DD genotype (P= 0.073; odds ratio: 2.64; 95%
confidence interval: 0.91–7.60) and a significantly higher
frequency of the D allele (P= 0.022; odds ratio: 2.43; 95%
confidence interval: 1.13–5.20) than male Rs. Multiple
forward stepwise regression analysis indicated that the
negative response to IFN-β therapy was associated with the
ACE-DD genotype in men ( β= 0.371; multiple R2 change:
0.132; P= 0.009) and a higher pretreatment relapse rate in
both men ( β=− 0.438; multiple R2 change: 0.135; P= 0.015)
and women ( β=− 0.208; multiple R2 change: 0.042;
P= 0.034). The ACE I/D polymorphism and pretreatment
relapse rate accounted for ∼ 26.7% of the IFN-β response
variability among the men in the sample. Further studies of
a larger number of MS patients from different populations
are necessary to evaluate these preliminary findings.
Pharmacogenetics and Genomics 00:000–000 Copyright ©
2017 Wolters Kluwer Health, Inc. All rights reserved.
Pharmacogenetics and Genomics 2017, 00:000–000
Keywords: angiotensin-converting enzyme,
angiotensin-converting enzyme insertion/deletion polymorphism,
interferon-β, multiple sclerosis, treatment response
aDepartment of Biology and Medical Genetics, bSchool of Medicine, University of
Rijeka, cDepartment of Neurology, Clinical Hospital Center Rijeka, Rijeka, Croatia,
dClinical Institute of Medical Genetics and eDepartment of Neurology, University
Medical Centre, Ljubljana, Slovenia
Correspondence to Smiljana Ristić, PhD, Department of Biology and Medical
Genetics, School of Medicine, University of Rijeka, Braće Branchetta 20, 51000
Rijeka, Croatia
Tel: + 385 516 51181; fax: + 385 516 78896;
e-mail: smiljana.ristic@medri.uniri.hr
Received 3 November 2016 Accepted 4 April 2017
Introduction
Multiple sclerosis (MS) is a multifactorial autoimmune dis-
ease that affects the central nervous system. MS is char-
acterized by chronic inflammation, multifocal demyelination,
and axon loss. Interferon-β (IFN-β), which has immunomo-
dulatory, anti-inflammatory, and antiproliferative effects, is
the first-line disease-modifying therapy (DMT) for MS
patients, but a clinical response does not occur in a large
proportion (30–50%) [1].
Recent pharmacogenomic observations suggest that the
efficacy of IFN-β therapy depends on genetic predis-
position. Despite numerous studies in the last decade
identifying gene variants that possibly influence the
complex response to IFN-β [1], reliable biomarkers of
treatment efficacy are lacking.
In recent years, components of the renin–angiotensin sys-
tem (RAS) have been shown to be involved in the
pathogenesis of MS [2]. Angiotensin-converting enzyme
(ACE) is the key enzyme activating the RAS by converting
angiotensin I (Ang I) into angiotensin II (Ang II), the major
effector molecule of the system. Ang II acts not only as a
potent vasoconstrictor but also as a proinflammatory factor
implicated in inflammatory/autoimmune demyelination.
Ang II stimulates brain vascular endothelial target cells,
influencing blood–brain barrier breakdown and allowing
macrophage infiltration of the brain parenchyma, increasing
microglia and astrocyte activation [3]. In addition, ACE
inactivates the potent vasodilator bradykinin through the
Kinin–Kallikrein system. All of the essential components of
the RAS and Kinin–Kallikrein system are present in the
brain. Linking both of these important systems, ACE
maintains the balance critical in the control of blood–brain
barrier permeability [3].
Recently, active plaques in the brains of MS patients
were reported to have elevated levels of both ACE and
Ang I receptor [4], which are also upregulated in the
inflamed spinal cords and immune systems of mice with
experimental autoimmune encephalomyelitis [2]. In
addition, increased levels of ACE have been found in the
serum [5] and cerebrospinal fluid [6,7] of MS patients.
Among several single nucleotide polymorphisms in ACE
that determine the activity of this enzyme and the level
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of Ang II, such as rs4343, rs4291, and the insertion/
deletion (I/D) polymorphism (rs1799752), the ACE I/D
polymorphism is the most studied RAS-related poly-
morphic variant and the only one investigated in the
etiology of MS until recently. This functional poly-
morphism in intron 16 of ACE (17q23) is characterized by
the presence or absence of a 287-bp Alu repetitive
sequence and accounts for ∼ 50% of the total phenotypic
variance of circulating and tissue ACE [8].
Animal studies of treatment with ACE inhibitors have
suggested that RAS blockade decreases central nervous
system demyelination and inflammation, reduces the
severity of experimental autoimmune encephalomyelitis
symptoms, and reverses the symptoms of established dis-
ease [2,4,9,10]. In humans, ACE inhibitors are used widely
in the treatment of cardiovascular disease. Recently,
Doerner et al. [11] reported the first study of the effects of
RAS inhibitors and β-blockers on disease activity in MS
patients. This clinical analysis failed to show a benefit of
concomitant administration of ACE inhibitors and IFN-β-1b
in MS patients compared with IFN-β-1b therapy only.
However, ACE I/D genotypes were not determined in the
patients analyzed in this study.
To date, several studies have reported an association
between the ACE I/D polymorphism and susceptibility
to MS [12,13], although a recent meta-analysis of four
studies carried out in Europeans of Slavic origin [12–15]
reported negative results [16]. However, no studies have
examined the effect of the ACE I/D polymorphism on
the response to DMT in MS patients. Therefore, we
hypothesized that the genetic variability of the ACE
gene may influence the response to IFN-β therapy in
Croatian and Slovenian MS patients.
Patients and methods
A total of 275 (211 women, 64 men) IFN-β-treated
patients who fulfilled the revised McDonald’s criteria for
MS [17] were recruited by collaborating clinical and
genetic centers in Croatia and Slovenia. The clinical
criteria for a response to IFN-β were applied after 2 years
of treatment. Patients with relapse-onset MS were divi-
ded into two groups: responders [Rs; no relapses and no
progression of Expanded Disability Status Scale (EDSS)
score] and nonresponders (NRs; having one or more
relapses and an increase in the EDSS score of at least 1
point confirmed at 6 months during the follow-up period)
[18]. Informed consent was obtained from all participants.
The study was carried out with the approval of the ethical
committees of both centers.
Genotyping was performed by a one-step PCR [8].
Fisher’s exact and χ2-tests were used to compare
the frequency of genotypes/alleles of the ACE I/D
polymorphism between groups and deviation from
Hardy–Weinberg equilibrium. The relationship between
the genotypes and normally distributed variables was Ta
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tested by analysis of variance. A multiple forward step-
wise regression analysis including polymorphism, relapse
rates, and EDSS score before IFN-β treatment was carried
out to evaluate the independent effect of the ACE I/D
polymorphism on the IFN-β treatment response. Partial
coefficients of correlation were calculated to test the cor-
relation between ACE I/D genotypes and the treatment
response, controlling for relapse rate and EDSS score
before IFN-β treatment.
Results
Of the 275 MS patients included in the study, 162
(58.9%) were classified as Rs and 113 (41.1%) as NRs to
IFN-β. Both groups had a similar mean age at disease
onset and mean EDSS at baseline, whereas NRs had a
higher relapse rate at baseline and more severe MS than
Rs at the study endpoint (Table 1).
The frequencies of ACE I/D genotypes and alleles in Rs
and NRs are shown in Table 2. The ACE I/D genotype
distributions did not deviate from Hardy–Weinberg
equilibrium in any group. We found no difference in
the ACE I/D genotype distribution or allele frequencies
between Rs and NRs in the overall patient group or
women. However, we observed a trend toward a greater
prevalence of the DD genotype (P= 0.073; odds ratio:
2.64, 95% confidence interval: 0.91–7.60) and a sig-
nificantly higher frequency of the D allele (P= 0.022;
odds ratio: 2.43; 95% confidence interval: 1.13–5.20) in
male NRs compared with male Rs.
The multiple forward regression analysis showed that the
presence of the DD genotype significantly predicted a
negative IFN-β therapy response in men (β= 0.371; mul-
tiple R2 change: 0.132; P=0.009), contributing toward
13.2% of the response variability. The significant impact of
the DD genotype on the IFN-β therapy response in this
group was confirmed by partial coefficients of correlation
analysis (r=0.434, P=0.009). In women, the IFN-β therapy
response did not significantly correlate with any ACE I/D
genotype. In addition, a significant negative dependence of
the response to IFN-β therapy on the pretreatment relapse
rate was found in both men (β=−0.438; multiple R2
change: 0.135; P=0.015) and women (β=−0.208; multiple
R2 change: 0.042; P=0.034). The pretreatment relapse
rate explained 13.5% of the response variability in men
with MS and 4.2% of the response variability in women
with MS.
Discussion
To the best of our knowledge, this study was the first to
examine an association between the ACE I/D poly-
morphism and different IFN-β treatment responses in
MS patients. The main finding is a sex-specific associa-
tion of the ACE I/D polymorphism with the IFN-β
treatment response in men. Although sex differences in
the response to DMT in MS have not been studied
extensively, recent findings indicate that men and
women do not have the same response to IFN-β [19].
In this preliminary study, we found a significant positive
association between a negative response to IFN-β treat-
ment and the DD genotype in men with MS. The ACE
DD genotype is associated with higher tissue and plasma
levels of ACE, whereas the ACE II genotype is associated
with lower ACE levels and the ID genotype with inter-
mediate levels [8]. We previously reported that the ACE
DD genotype and D allele may contribute toward an ele-
vated risk of MS among Croatian and Slovenian men [12];
thus, the same genetic background may influence both
individual IFN-β treatment responses and MS suscept-
ibility. This finding seems to be especially interesting
considering the more profound effect of the ACE I/D
polymorphism on men compared with women in previous
studies in which the ACE DD genotype conferred an
increased risk of hypertension [20] and premature myo-
cardial infarction in men [21]. Furthermore, one recent
study reported that a number of cardiovascular genetic
factors are associated with increased MS risk, suggesting
that the pathobiology of these diseases overlaps [22].
As the frequency of relapse 2 years before IFN-β treat-
ment differed significantly between Rs and NRs, we
further evaluated whether the relapse rate is a reliable
predictor of the treatment response, either alone or in
combination with the ACE I/D genotype. A higher fre-
quency of relapse 2 years before IFN-β treatment was
associated with a negative response to IFN-β therapy in
Table 2 Frequency of angiotensin-converting enzyme insertion/deletion genotypes and alleles among the multiple sclerosis patients in
this study
Males (n=64) Females (n=211) Total (n=275)
Genotype/allele
IFN-β R
(n=40)
IFN-β NR
(n=24) P
IFN-β R
(n=122)
IFN-β NR
(n=89) P
IFN-β R
(n=162)
IFN-β NR
(n=113) P
ACE I/D
DD 11 (27.5) 12 (50.0) 0.073 32 (26.3) 22 (24.7) 0.804 43 (26.5) 34 (30.1) 0.520
ID 18 (45.0) 10 (41.7) 0.795 69 (56.5) 51 (57.3) 0.914 87 (53.7) 61 (54.0) 0.964
II 11 (27.5) 2 (8.3) 0.081 21 (17.2) 16 (18.0) 0.885 32 (19.8) 18 (15.9) 0.419
D 40 (50.0) 34 (70.8) 0.022 133 (54.5) 95 (53.4) 0.817 173 (53.4) 129 (57.1) 0.393
I 40 (50.0) 14 (29.2) – 111 (45.5) 83 (46.6) – 151 (46.6) 97 (42.9) –
Data are presented as n (%).
ACE, angiotensin-converting enzyme; I/D, insertion/deletion; IFN-β, interferon-β; NR, nonresponder; R, responder.
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both men and women. The findings are consistent with
those of Sorensen et al. [23] and Sellebjerg et al. [24], who
identified pretreatment relapse rate as an important
predictor of a negative response to IFN-β treatment in a
large cohort of Danish patients.
The current study has several limitations. First, although
our study had 100% power to detect a 2.0-fold increase in
ACE D allele frequency in men and a 1.8-fold increase in
women, the relatively small number of participants,
especially men, limits our conclusions on the effect of
the ACE I/D polymorphism on the IFN-β treatment
response. Second, our study is based on a short period of
observation (2 years) because we could not follow the
patients for a longer period of time on the same drug,
which certainly would have allowed for a better assess-
ment of the IFN-β response [25].
Finally, with respect to possible comorbidities related to
the ACE system, none of our patients were on ACE
inhibitors or other drugs (hypolipidemic, antiplatelet)
related to cardiovascular disease. However, in a small
number of patients, we cannot rule out concomitant use
of antispastic/anticonvulsant/anxiolytic drugs that could
have potentially modulated MS severity.
Conclusion
The present study shows that the ACE DD genotype is
associated with a negative response to IFN-β therapy in
men. The ACE I/D polymorphism and pretreatment
relapse rate accounted for ∼ 26.7% of the IFN-β response
variability in this patient group, indicating the involve-
ment of many other genes and/or factors in the response
to treatment. As the RAS is a complex system that may
influences autoimmune responses, modulates T cells,
and acts on macrophages through different signaling
pathways, future studies should analyze additional poly-
morphisms in RAS genes and correlate them with the
ACE I/D polymorphism within the scope of the response
to DMT in MS. In addition, further studies of a larger
number of MS patients from different populations are
necessary to evaluate these preliminary findings.
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